Table 4 Molecular targeted therapies with demonstrated preclinical activity as radiosensitizers

Epidermal Growth Factor Receptor inhibitors

Cetuximab

Gefitinib

Trastuzumab

CI-1033 (pan-ErbB tyrosine kinase inhibitor)

Farnesyl Transferase Inhibitors

FTI-277

L744832

BIM-46068

Ras-Mediated Downstream Pathways inhibitors

AS-ON Raf

PI3K inhibitor: LY294002

PI3K inhibitor: wortamannin

AS-ON p21

MEK inhibitor

Agents that target apoptosis, cell cycle, NF-Kappa-B

Flavopiridol

PS-341

UCN-01

COX-2 Inhibitors

SC-236

NC-398

Rofecoxib

Antiangiogenic Agents

mAb-VEGF

SU5416

SU5416

SU6668

mAb-VEGF-2

Angiostatin

Endostatin

Histone deacetylase inhibitors

Valproic acid

MS275

SAHA